VEGFA and non-small cell lung carcinoma: In summary, our results show that NSCLC patients with positivity of blood MUC1 and VEGF mRNA seem to have poor outcomes with gefitinib treatment, in terms of PFS, OS and response, than those with negativity of the two markers.